SCHEMBL16776028

SCHEMBL16776028

COc1cc(NC(=O)N2c3nc(-c4ccnc(C)c4)ccc3NCC[C@H]2C)ncn1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ FGFR4 P22455 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ ALOX5AP P20292 1/20 0.38
▸ KCNH2 Q12809 1/20 0.38
▸ RPS6KA2 Q15349 2/20 0.37
▸ FAAH O00519 1/20 0.36
▸ ABL1 P00519 1/20 0.35
▸ MTOR P42345 2/20 0.34
▸ PDK1 Q15118 1/20 0.34
▸ PDK2 Q15119 1/20 0.34
▸ PDK3 Q15120 1/20 0.34
▸ PDK4 Q16654 1/20 0.34
▸ MAPK1 P28482 6/20 0.34
▸ TBK1 Q9UHD2 1/20 0.33
▸ DYRK1A Q13627 1/20 0.33
▸ WNT3A P56704 1/20 0.33
▸ HPGDS O60760 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16776032 0.90 KCNH2 (0.41) FGFR4CYP2C9ALOX5APKCNH2RPS6KA2
SCHEMBL16776037 0.88 FGFR4 (0.37) FGFR4CYP2C9ALOX5APKCNH2RPS6KA2
SCHEMBL16775908 0.87 FAAH (0.39) FGFR4CYP2C9ALOX5APKCNH2RPS6KA2
SCHEMBL16776203 0.87 ABL1 (0.36) RPS6KA2FAAHABL1MTORMAPK1
SCHEMBL16776209 0.86 KCNH2 (0.42) FGFR4CYP2C9ALOX5APKCNH2RPS6KA2
SCHEMBL19670266 0.85 FGFR4 (0.41) FGFR4CYP2C9ALOX5APKCNH2RPS6KA2
SCHEMBL16776041 0.85 FAAH (0.40) FGFR4CYP2C9ALOX5APKCNH2RPS6KA2
SCHEMBL16776233 0.84 DYRK1A (0.34) RPS6KA2ABL1MTORMAPK1DYRK1A
SCHEMBL16776143 0.83 RPS6KA2 (0.39) FGFR4CYP2C9ALOX5APKCNH2RPS6KA2
SCHEMBL16776231 0.83 ABL1 (0.38) ABL1MTORMAPK1WNT3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150152108-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2015-06-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152108-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 FGFR4 1754/4885CYP2C9 2535/4885ALOX5AP 3669/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback